Ryan Cross

scienceboss.bsky.social

21 October 2026 12:17

Astellas partners with Boston ‘miniproteins’ startup AI Proteins. Details in my exclusive for @endpts.com: - endpoints.news/exclusive-as...

Ryan Cross

scienceboss.bsky.social

16 October 2026 14:59

For decades, Rudolph Tanzi has dreamt of a “little white pill” to prevent Alzheimer’s disease. Now, his startup Acta Pharma is getting ready to test a drug that could block the buildup of amyloid plaques. My deep dive for @endpts.com has the details: endpoints.news/rudy-tanzi-h...

Ryan Cross

scienceboss.bsky.social

16 October 2026 14:59

Arrowhead’s brain-targeting siRNA, administered as a subcutaneous injection, lowers the Alzheimer’s protein tau in early study. Lots of work ahead here, but good news for delivery tech designed to cross the blood-brain barrier. My story for @endpts.com: - endpoints.news/arrowheads-b...

Ryan Cross

scienceboss.bsky.social

16 October 2026 14:58

We've got a great event at @endpts.com starting up at 11:00 am ET. I'm interviewing Stanford's @lecong.bsky.social, Basecamp's John Finn and Waterfall Scientific's Melissa Moore (former Moderna CSO) about the intersection of AI and genetic medicine. Tune in here: events.endpoints.news/aiday2026/

Ryan Cross

scienceboss.bsky.social

12 June 2026 14:45

Lilly is partnering with Ascidian to develop RNA "exon editing" therapies for genetic kidney diseases (an interesting drug delivery challenge!) It's at least the 6th deal Lilly has struck in just over a week, reaching a total deal value of $10B. More in @endpts.com : endpoints.news/lilly-strike...